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Cell and gene therapies (CGTs) are progressively entering into clinical practice in different parts of the world. The Interna-
tional Society for Cell & Gene Therapy (ISCT), a global scientific society, has been committed since 1992 to supporting and
developing knowledge on clinical applications of CGTs. Considering the number of products that have been progressively
approved and, in some cases, withdrawn in recent years, the ISCT would like to present a brief annual report on CGTs with
marketing authorization (MA) in different regions. This article reflects the dynamic momentum around authorized CGTs
coinciding with the parallel increase of unproven approaches where cells are delivered without appropriate and rigorous sci-
entific and regulatory assessment and authorization. This is intended to be a living document with a yearly update linked to a
dedicated section of the ISCT website for faster adjustments. The aim is to ultimately inform, by periodic snapshots, the sci-
entific community, healthcare stakeholders and patient associations on authorized CGT products as a way to increase com-
munication around the approved therapeutic approaches charged with heightened expectations.Introduction
The International Society for Cell & Gene Therapy
(ISCT) is committed to translating cellular therapy
into safe and effective treatments to improve
patients’ lives while minimizing and balancing risks
for patients. Being aware that many unproven or
insufficiently proven cell-based treatments are
commercially available for hopeful individuals
seeking cures or health improvement for a variety
of conditions, the ISCT created the ISCT Presi-
dential Task Force (PTF) on the Use of Unproven
Cellular Therapies (UCT) in 2014. The PTF-
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tices worldwide [1,2].
In line with the above goals, the PTF-UCT has
launched several initiatives including providing
updated information on approved cellular thera-
pies. For a list of PTF-UCTauthored resources
visit http://www.celltherapysociety.org/page/UCT.
In this document the PTF-UCT has summarized
cell, tissue and gene medicinal products authorized
for commercialization by regions/countries, to help
patients seeking safe and effective treatments. We
have not included any products that are categorized
as medical devices, even if they are cell-based. If
a patient lives in one of the regions/countriesAdvanced Therapies/Iniciativa Andaluza en Terapias Avanzadas, Junta de
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sional or a business is offering a cell-based treat-
ment not listed, they should ask whether they are
going to receive the treatment as part of a clinical
trial. If not, the ISCT recommends asking for more
information about the “regulatory status” of the
treatment they are going to receive to make an
informed decision.Definitions and principles
Human cell or tissue-based products are highly het-
erogeneous and regulatory authorities will always
apply their rulings on a case-by-case basis. Neverthe-
less, at present, most of the cell- and tissue-based
products are considered biological medicinal products
in those countries with more developed regulatory
structures. The development of safe and effective
“proven” cell therapies requires testing these medici-
nal products according to some general principles [3].
Before administration into humans, both biological
activity and toxicity of the investigational medicinal
product must be tested in relevant animal model(s).
Researchers must then seek approval of an institu-
tional review board (IRB) for all centers involved in
the clinical trial as well as an authorization from the
national regulatory agencies of the countries where
patients will be recruited, irrespective of their nation-
alities. The sponsor’s duties also include ensuring: (i)
that there is an insurance policy in place to cover any
liability, (ii) that recruitment of subjects is done after
appropriate informed consent and (iii) that medicinal
product batches for release conform to specifications.
If the regulatory bodies determine that quality, safety
and efficacy of a cell- or tissue-based medicinal prod-
uct are sufficiently established through successful clin-
ical phases (clinical trial phase 1, 2 and 3), then the
next step is to apply for marketing authorization
(MA). After that, the company that holds the MA can
commercialize the medicinal product in the countries
in which the product has been granted MA. In some
cases, MA is provisional and post-marketing surveil-
lance studies are required. Of note, some countriesTable I. List of cell/tissue/gene products with MA in Australia by TGA.
Name (MA holder) Product description and
indication(s)
Product cate





in treatment of carti-
lage lesions associated
with the knee, patella
and ankle
Cell therapy
TGA, Therapeutic Goods Administration.permit exceptions to this authorization rule depending
on the nature of the medicinal product, be it industrial
or otherwise. In any case, the use of a medicinal prod-
uct has to be supervised by a regulatory body.Identified cell and gene therapies with MA
We have identified and listed cell and gene therapies
(CGTs) with MA based on available information,
considering as a source of trustworthy information
the regulatory body web resources, official press
release by the interested companies or other source
of data as indicated in Tables IX where countries/
regions are listed in alphabetical order. The list has
been updated as of September 15, 2018, unless oth-
erwise specified.
In Figure 1, we present the distribution of
authorized CGT products by region. In addition,
we have listed (Table XI) the CGT approaches
that have received a Regenerative Medicine
Advanced Therapy (RMAT) designation by the
United States Food and Drug Administration
(USFDA) [4] but have not been approved as of
September 2018. In Figure 2, we have categorized
CGT products with MA worldwide in three
different ways, namely, by product, therapy and
disease type. Finally, in Figure 3 we present CGT
products according to the year in which they
received MA.
Several products are currently available in dif-
ferent regions but have the same MA holder
(YESCARTA, KYMRIAH, IMLYGIC, RMS Oss-
ron/OSSGROW and Chondron/CARTIGROW).
These products are taken into account only once in
Figures 2 and 3, leading to a total number of 44
unique products.Discussion and conclusions
The goal of this article is to provide a quick reference
for anyone interested in a snapshot, to be updated
annually, of the CGT landscape worldwide. This list
may not be exhaustive and additional CGT productsgory Date of MA Current status Additional
information
product 26-Mar-2017 Still in market Click here for
link to TGA
website
Table III. List of cell/tissue/gene products with MA in China by CSFDA.
Name (MA holder) Product description and
indication(s)





expressing p53 for treat-
ment of head and neck
squamous cell carcinoma
Gene therapy product Oct-2003 Still in market Click here
CSFDA, Chinese Food and Drug Administation.
Table II. List of cell/tissue/gene products with MA in Canada by Health Canada (March 2018).
Name (MA holder) Product description and
indication(s)








the treatment of pediatric
and young adult patients
325 y with B-cell ALL who
are refractory, have relapsed
after allogeneic SCT or are
otherwise ineligible for SCT,
or have experienced second
or later relapse and for the
treatment of adult patients
with relapsed or refractory
large B-cell lymphoma after
two or more lines of systemic
therapy including DLBCL
not otherwise specified, high-
grade B-cell lymphoma and













stromal cells for the manage-











ALL, acute lymphoblastic leukemia; SCT, stem cell transplantation; DLBCL, diffuse large B-cell lymphoma; aGVHD, acute graft-versus-
host disease.
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knowledge, no cell/tissue/gene products have been
authorized for marketing in Brazil, Hong Kong,
Israel, Malaysia, Singapore and Taiwan as of Sep-
tember 2018.
We have identified 44 unique products, 37 of
them are cell and tissue therapies (84%) and mainly
autologous (55%) (Figure 2). As far as targeted dis-
eases are concerned, more than one third of the
products are intended for the treatment of oncologi-
cal or hematologic diseases.
As shown in Figure 3, the number of products with
MA has increased in recent years. For example, those
authorized from 2015 to September 2018 represent
45%. Unfortunately, there has been a parallel increase
in the number of businesses offering unproven and
unlicensed cell-based interventions [5,6].Even though the distribution of authorized CGTs
shows important differences among countries or
regions, it is not our intention to debate the complex
financial, societal and scientific reasons behind these
differences or the impact of different regulatory sys-
tems on the number of marketed products. As mem-
bers of the ISCT PTF-UCT, our main objective is to
help patients make informed decisions before receiv-
ing a cell or gene treatment so that they can avoid
being exposed to unproven and unlicensed cell inter-
ventions. For that purpose, we aim to provide a reli-
able, up-to-date resource where patients or
professionals can check whether a cell or gene therapy
has been approved by a regulatory/medicine agency.
As mentioned before, the ISCT recommends
asking for information about the “regulatory status”
of the treatment patients are going to receive to make
Table IV. List of Cell/Tissue/Gene Products with MA in the European Union by EMA.
Name (MA holder) Product description and
indication(s)





fied autologous T cell immuno-
therapy indicated for the
treatment of adult patients with
relapsed or refractory DLBCL
and PMBCL, after two or more
lines of systemic therapy
GTMP 23-Aug-2018 Details of MA condi-
tions not displayed at









fied autologous T-cell immuno-
therapy indicated for the
treatment of pediatric and young
adult patients up to 25 y of age
with B-cell ALL that is refrac-
tory, in relapse post-transplanta-
tion or in second or later relapse,
and for the treatment of adult
patients with relapsed or refrac-
tory DLBCL after two or more
lines of systemic therapy
GTMP 27-Aug-2018 Details of MA condi-
tions not displayed at







Expanded allogeneic adipose stem
cells as a suspension for injection
for the treatment of complex
perianal fistulas in patients with
Crohn’s disease
SCTMP 27-Mar-2018 The company will com-



























Donor’s T lymphocytes genetically
modified with a suicide gene as a
control mechanism for GVHD
after haploidentical bone mar-
row transplantation








Autologous CD34+ cells trans-
duced with a retroviral vector
that encodes for the human
ADA cDNA sequence for severe
combined immunodeficiency
due to ADA deficiency









from a herpex simplex virus-1
genetically engineered to infect
and replicate within melanoma
cells and to produce GM-CSF
for unresectable melanoma








human corneal epithelial cells
containing stem cells for severe
limbal stem cell deficiency





EMA, European Medicines Agency; ATMP, Advanced Therapy Medicinal Product; PMBCL, primary mediastinal large B-cell lymphoma;
ADA, Adenosine deaminase; cDNA, complementary DNA; TEP, Tissue Engineered Product; GTMP, Gene Therapy Medicinal Product;
SCTMP, Somatic Cell Therapy Medicinal Product; EC, European Commission.
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Table V. List of cell/tissue/gene products with MA withdrawn or suspended in the European Union by EMA.
Name (MA holder) Product description and
indication(s)






















drocytes for repairing knee
cartilage defects










lipoprotein lipase gene vari-
ant in a adeno-associated
viral vector) for adult patients
with familiar lipoprotein
lipase deficiency





did not apply for








gous cartilage cells expanded
ex vivo for repairing knee car-
tilage defects
TEP 5-Oct-2009 The product was reim-
bursed in 3 countries.
Withdrawn: 30-Nov-
2016. Requested by





Table VI. List of cell/tissue/gene products with MA in India by DCGI.
Name (MA holder) Product description and
indication(s)





























cells for treatment of
prostate, ovarian, colorec-












stromal cells for treat-
ment of critical limb





May-2016 In market, limited release (200




DCGI, Drug Controller General of India.
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patients living in one of the regions/countries
included in the document who seek safe and effective
treatments, should a healthcare professional or a
business offer a CGT that is neither listed nor part of
a clinical trial.Acknowledgments
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Table VII. List of cell/tissue/gene products with MA in Japan by PMDA.
Name (MA holder) Product description and
indication(s)















sheet product for the treat-





Click here for link to
PMDA website








Click here for link to
PMDA website
JACE (J-TEC) Autologous cultured epi-








Click here for link to
PMDA website
PMDA, Pharmaceuticals and Medical Devices Agency.
Table VIII. List of cell/tissue/gene products with MA in New Zealand by MEDSAFE.
Name (MA holder) Product description and
indication(s)






stromal cells indicated for the
rescue of patients NLT 6 mo
to 17 y of age with aGVHD,
refractory to treatment with
systemic corticosteroid ther-




14-Jun-2012 Approval lapsed Click here for
link to MED
SAFE website
MEDSAFE, Medicines and Medical Devices Safety Authority; NLT, Not Lower Than.
Table IX. List of cell/tissue/gene products with MA in South Korea by MFDS.
Name (MA holder) Product description and
indication(s)





Composite cell product (allo-
geneic skin-derived keratino-
cytes suspended in a
thermosensitive hydrogel) for
deep 2nd degree burns
Cell therapy
product





Autologous bone marrow mes-
enchymal stromal cell ther-

























Human umbilical cord blood-
derived mesenchymal stro-
mal cells for the treatment of
knee articular cartilage
defects in patients with oste-
oarthritis (ICRS grade IV)
Cell therapy
product
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Table IX. (Continued).
Name (MA holder) Product description and
indication(s)













































sheet) for deep 2nd degree














blasts for focal bone forma-





















































tinocytes for deep 2nd degree
burns that cover >30% of
TBSA and 3rd degree burns
that cover >10% of TBSA
Cell therapy
product






deep 2nd degree burns that
cover >30% of TBSA and














cytes for focal cartilage defect




30-Jan-2001 Still in market Click here for
link to MFDS
website
MFDS, Ministry of Food and Drug Safety; ICRS, International Cartilage Regeneration & Joint Preservation Society; LVEF, left ventricular
ejection fraction; TBSA, Total Burn Surface Area.
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Table X. List of cell/tissue/gene products with MA in the United States by USFDA.





For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that











Adeno-associated virus vector-based gene
therapy indicated for the treatment of











A CD19-directed genetically modified
autologous T-cell immunotherapy indi-
cated for the treatment of adult patients
with relapsed or refractory large B-cell
lymphoma after two or more lines of
systemic therapy, including DLBCL
not otherwise specified, primary medi-
astinal large B-cell lymphoma, high-
grade B-cell lymphoma and DLBCL
arising from follicular lymphoma
Gene therapy
product








autologous T-cell immunotherapy indi-
cated for the treatment of patients up to
25 y of age with B-cell precursor ALL









Autologous cultured chondrocytes on a
porcine collagen membrane for the
repair of single or multiple symptom-
atic, full-thickness cartilage defects of











For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that









For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that










Genetically modified oncolytic viral ther-
apy indicated for the local treatment of
unresectable cutaneous, subcutaneous
and nodal lesions in patients with mela-
noma recurrent after initial surgery
Gene therapy
product









13-Jun-2013 Still in market
(continued)
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Table X. (Continued).




procedures in conjunction with an
appropriate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that









For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that











For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that












For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that









Allogeneic cultured keratinocytes and
fibroblasts in bovine collagen (cellular
sheets) for topical (non-submerged)
application to a surgically created vas-
cular wound bed in the treatment of
mucogingival conditions in adults
Tissue engi-
neered product







For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that










Autologous fibroblasts for improvement
of the appearance of moderate-to-
severe nasolabial fold wrinkles in adults
Cell therapy
product






Autologous cellular immunotherapy indi-
cated for the treatment of asymptomatic





29-Apr-2010 Still in market Click here for
link to FDA
website
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Figure 1. Number of cell, tissue and gene products with MA per region. *Eight products based on cord blood hematopoietic progenitors for
unrelated donor hematopoietic progenitor cell transplantation have been included in the US’s total number. These hold a MA license only
in the US. Similar products are available in most countries as cell transplants and not as marketed products. The number of products pre-
sented in this figure does not include either products with Regenerative Medicine Advanced Therapy (RMAT) designation (United States
Food and Drug Administration [USFDA]) or products with suspended MA.
Table XI. List of cell/tissue/gene products with RMATDesignation [4] in the United States by USFDA (Sep-2018).
Name (MA holder) Product description and indication
(s)








AAV-mediated gene therapy for
the treatment of XLMTM, a
rare monogenic disease caused











Off-the-shelf human myeloid pro-
genitor cells for the prevention of
serious bacterial and fungal
infections in patients with de







AAV-mediated gene therapy for
the treatment of Parkinson’s dis-
ease in patients with motor fluc-








CD34+ cell therapy program for








AAV-mediated gene therapy for
the treatment of choroideremia,
a rare, degenerative, genetic reti-







AAV-mediated gene therapy for
the treatment of Sanfilippo syn-
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Table XI. (Continued).
Name (MA holder) Product description and indication
(s)










brane for use in the treatment of






Allogeneic cell therapy (cardio-
sphere-derived cells) that is cur-
rently in clinical development for























MPC therapy in the treatment of
patients with heart failure with













Multistem (Athersys) Proprietary stem cell product for








embryonic stem cells for treat-








hematopoietic stem cells for
treatment of transfusion-depen-
dent b-thalassemia (also known














Autologous skin cell product for








lar (mesenchymal cells, mono-
cytes and alternatively activated
macrophages) product for the
treatment of patients with





jCell (jCyte) Adult retinal progenitor cells for




RVT-802 (Enzyvant) Allogeneic thymic tissue for the
treatment of primary immune






















AAV, adeno-associated virus; XLMTM, X-linked Myotubular Myopathy; AML, acute myeloid leukemia; OA, osteoarthritis; RDEB, reces-
sive dystrophic epidermolysis bullosa; MPC, mesenchymal precursor cell; LVADs, left ventricular assist devices; SCD, sickle cell disease;
HSCT, hematopoietic stem cell transplantation; RP, retinitis pigmentosa; cDGS, complete diGeorge Syndrome; HAV, human acellular
vessel.
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Figure 2. Cell, tissue and gene products with MA worldwide (44 unique products) organized by (A) product type, (B) therapy type and (C)
disease type. “Cell Therapy” products in (B) also include tissue engineered products. Eight products based on cord blood hematopoietic
progenitors for unrelated donor hematopoietic progenitor cell transplantation have been included in the total number. These hold a MA
license only in the US. Similar products are available in most countries as cell transplants and not as marketed products. The number of
products presented in this figure does not include either products with RMAT designation (USFDA) or products with suspended MA.
GVHD, graft-versus-host disease.
Figure 3. Cell, tissue and gene products with MA worldwide (44 unique products) organized by year of MA. Eight products based on cord
blood hematopoietic progenitors for unrelated donor hematopoietic progenitor cell transplantation have been included in the total number
These hold a MA license only in the US. Similar products are available in most countries as cell transplants and not as marketed products
The number of products presented in this figure does not include either products with RMAT designation (USFDA) or products with sus-
pendedMA.
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